tiprankstipranks
Trending News
More News >
Medicus Pharma Ltd (MDCX)
NASDAQ:MDCX

Medicus Pharma Ltd (MDCX) AI Stock Analysis

Compare
45 Followers

Top Page

MD

Medicus Pharma Ltd

(NASDAQ:MDCX)

Rating:35Underperform
Price Target:
Medicus Pharma Ltd's financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.
Positive Factors
Clinical Trial Progress
The interim data for the trial demonstrated a remarkable >60% complete response rate, indicating significant potential for a non-invasive alternative to Mohs surgery.
Financial Stability
The company has a pro-forma cash balance of $10.8 million, providing financial runway until the second half of 2025 through interim and full Phase 2 trial data.
Market Opportunity
Nodular basal cell carcinoma affects approximately 3 million patients annually in the US, presenting a significant market opportunity for SkinJect.
Negative Factors
Regulatory Challenges
A request has been made for a Type C meeting with the FDA.
Trial Expansion Risks
The expansion of the trial to include more patients and additional sites in Europe enhances the company's footprint in the basal cell carcinoma space, potentially attracting partners.

Medicus Pharma Ltd (MDCX) vs. SPDR S&P 500 ETF (SPY)

Medicus Pharma Ltd Business Overview & Revenue Model

Company DescriptionMedicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
How the Company Makes MoneyMedicus Pharma Ltd makes money primarily through the sale of its pharmaceutical products and therapies to healthcare providers, hospitals, and pharmacies. The company generates revenue through direct sales, licensing agreements, and strategic partnerships with other pharmaceutical and biotech companies. Additionally, Medicus Pharma Ltd invests in research and development to discover new treatments, which can lead to new revenue streams through patents and proprietary products. Collaboration with research institutions and participation in clinical trials also contribute to its earnings. By maintaining a robust pipeline of innovative drugs and expanding its market presence, the company aims to sustain and grow its revenue base.

Medicus Pharma Ltd Financial Statement Overview

Summary
Medicus Pharma Ltd faces significant financial challenges with consistent losses and no revenue generation. Despite some balance sheet improvements, the reliance on financing and negative cash flow highlight potential instability.
Income Statement
5
Very Negative
Medicus Pharma Ltd has shown consistent negative EBIT and net income across multiple years with no revenue reported. This indicates a lack of sales or revenue generation capability, which is a significant concern for future profitability.
Balance Sheet
25
Negative
The company's balance sheet shows improvement in equity from negative to positive over recent years, indicating some financial recovery. However, the historical high liabilities and negative equity in prior years highlight potential financial instability. The current debt-to-equity ratio is low, which is a positive aspect.
Cash Flow
10
Very Negative
Consistently negative free cash flow indicates ongoing challenges in generating cash from operations. The company relies heavily on financing activities to support operations, which could be unsustainable in the long term.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.000.000.000.000.00
EBIT
-14.52M-11.18M-4.73M-978.42K-1.44M
EBITDA
-13.54M-10.62M-2.66M-1.17M-1.94M
Net Income Common Stockholders
-9.36M-10.62M-5.31M-1.69M-2.06M
Balance SheetCash, Cash Equivalents and Short-Term Investments
3.98M4.16M1.72M267.65K78.51K
Total Assets
5.66M5.65M1.89M282.65K78.51K
Total Debt
294.69K322.27K0.001.53M667.93K
Net Debt
-3.69M-3.84M-1.72M1.26M589.42K
Total Liabilities
3.51M2.51M781.61K12.48M10.58M
Stockholders Equity
2.15M3.13M1.11M-12.20M-10.51M
Cash FlowFree Cash Flow
-13.01M-10.25M-4.16M-1.06M-1.45M
Operating Cash Flow
-13.01M-10.25M-4.16M-1.06M-1.45M
Investing Cash Flow
0.000.000.000.000.00
Financing Cash Flow
16.41M12.69M5.61M1.25M882.38K

Medicus Pharma Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4.86
Price Trends
50DMA
4.27
Negative
100DMA
3.76
Negative
200DMA
3.52
Negative
Market Momentum
MACD
-0.64
Positive
RSI
35.32
Neutral
STOCH
36.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDCX, the sentiment is Negative. The current price of 4.86 is above the 20-day moving average (MA) of 4.40, above the 50-day MA of 4.27, and above the 200-day MA of 3.52, indicating a bearish trend. The MACD of -0.64 indicates Positive momentum. The RSI at 35.32 is Neutral, neither overbought nor oversold. The STOCH value of 36.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDCX.

Medicus Pharma Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.37B3.26-45.10%3.30%16.81%0.02%
52
Neutral
$92.33M13.0717.69%16.51%
48
Neutral
$45.76M-505.14%-11.21%47.20%
39
Underperform
$88.22M-307.27%-100.00%51.19%
35
Underperform
$41.17M-1882.04%
28
Underperform
$33.95M-916.17%45.15%
$65.51M-111.42%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MDCX
Medicus Pharma Ltd
2.60
-0.70
-21.21%
MRSN
Mersana Therapeutics
0.37
-1.67
-81.86%
WHWK
Whitehawk Therapeutics
1.96
0.33
20.25%
RVPH
Reviva Pharmaceuticals Holdings
0.73
-0.72
-49.66%
MIST
Milestone Pharmaceuticals
1.65
0.26
18.71%
IMMX
Immix Biopharma
2.35
0.30
14.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.